Previous Article in Journal
AI-Generated Antibiotic Therapies for Acute Periprosthetic Joint Infections with Implant Retention in Comparison with an Interdisciplinary Team
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance in Mycobacterium tuberculosis Isolates from Kazakhstan

1
National Center for Biotechnology, Astana 010000, Kazakhstan
2
Department of General Biology and Genomics, L. N. Gumilyov Eurasian National University, Astana 010000, Kazakhstan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Antibiotics 2026, 15(1), 26; https://doi.org/10.3390/antibiotics15010026 (registering DOI)
Submission received: 6 November 2025 / Revised: 4 December 2025 / Accepted: 13 December 2025 / Published: 30 December 2025

Abstract

Background/Objectives: Multidrug-resistant tuberculosis remains a critical public health challenge in Kazakhstan, yet the genomic determinants contributing to its emergence are still insufficiently understood. Although the quantity of genomic studies from Central Asia and the wider post-Soviet region has increased in recent years, the involvement of DNA repair and genome maintenance pathways in the development of resistance within Kazakhstan has not been comprehensively explored. Methods: In this study, we performed whole-genome analysis of 175 Mycobacterium tuberculosis clinical isolates collected across Kazakhstan between 2010 and 2022 to evaluate the contribution of single-nucleotide polymorphisms in DNA replication, repair, and recombination (3R) genes to the evolution of drug resistance. Results: Alongside well-established resistance mutations in gyrA, we identified recurrent variants in 3R-associated loci (genes involved in DNA replication, repair, and recombination)—including polA, uvrC and ligC—that were enriched among drug-resistant isolates, suggesting a broader role for genome maintenance pathways in facilitating resistance evolution under treatment pressure. Conclusions: These findings provide the first region-specific genomic insights into 3R gene variation in Kazakhstani M. tuberculosis isolates.

1. Introduction

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of infectious mortality worldwide, with an estimated 10.7 million incident cases and 1.23 million deaths in 2024 alone, underscoring its status as a persistent global health crisis exacerbated by diagnostic delays and underfunding [1,2]. The advent of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) forms has intensified this burden, with approximately 390,000 new MDR/RR-TB (rifampicin-resistant tuberculosis) cases reported globally in 2024, driven by inadequate treatment adherence, poor infection control, and the pathogen’s remarkable adaptability [1,3]. Kazakhstan exemplifies this challenge, ranking among the 30 high MDR-TB burden countries for 2021–2025 [4,5,6,7]. One contributing factor is the widespread presence of the Beijing lineage, which is associated with increased transmissibility and a higher likelihood of drug resistance. These biological factors intersect with broader social and economic challenges [8,9].
In contrast to pathogens such as Klebsiella pneumoniae and Escherichia coli, which commonly acquire antimicrobial resistance through horizontal transfer of extended-spectrum β-lactamase (ESBL) and other resistance determinants carried on mobile plasmids that can move between strains and even across species, Mycobacterium tuberculosis follows a fundamentally different evolutionary path. Because M. tuberculosis lacks plasmids and engages in minimal recombination, it cannot gain resistance via horizontal gene transfer; instead, drug resistance arises solely through spontaneous chromosomal mutations—predominantly SNPs, small insertions or deletions, and occasional larger structural variants—that occur during replication and become fixed under selective pressure from inadequate or interrupted therapy. As a result, whereas resistant healthcare-associated infections in plasmid-bearing bacteria may emerge through rapid plasmid dissemination or clonal spread, M. tuberculosis accumulates resistance mutations slowly and clonally, at a modest baseline mutation rate (0.3–0.6 SNPs per genome per year), ultimately enabling the stepwise emergence of MDR- and XDR-TB [10,11,12,13].
Drug-resistance in Mycobacterium tuberculosis arises through mutations that typically alter drug targets, prodrug activators or efflux regulators, thereby conferring resistance via mechanisms such as target modification or enzymatic inactivation. Although these mutations often impose a fitness cost, this burden can be mitigated through compensatory changes or favorable epistatic interactions that restore growth rates without reversing resistance. Indeed, epistasis among resistance-conferring and compensatory mutations, together with the broader genetic background of the strain, profoundly shapes the biology, persistence and epidemiology of drug-resistant TB. For instance, mycobacteria harboring both an rpoB mutation (rifampicin resistance) and a fluoroquinolone-resistance mutation in gyrA can display higher competitive fitness than strains carrying either mutation alone. Similarly, strains combining an rpoB mutation with a compensatory mutation in RpoC show enhanced fitness relative to those with only the rpoB mutation and exhibit an increased likelihood of acquiring additional resistance mutations, promoting the amplification of resistance. Collectively, these examples illustrate how epistatic interactions can reduce fitness costs and facilitate the evolution and spread of multidrug-resistant strains. A more comprehensive understanding of these relationships will be essential for strengthening antibiotic resistance surveillance and guiding the deployment of new TB treatment regimens [14,15,16].
The most prevalent chromosomal markers of resistance include mutations in rpoB for rifampicin, katG and inhA promoter for isoniazid, embB for ethambutol, pncA for pyrazinamide, rpsL and rrs for streptomycin, and gyrA for fluoroquinolones [17,18,19]. While these canonical loci account for the majority of phenotypic resistance, hypermutability driven by defects in DNA replication, repair, and recombination (3R) genes accelerates adaptation to antibiotics by elevating genome-wide mutation rates and increasing the probability of acquiring resistance-conferring variants in drug targets [20,21]. SNPs in 3R genes—such as those involved in base excision repair (BER), nucleotide excision repair (NER), or homologous recombination (HR)—are enriched in MDR/XDR isolates, particularly within Beijing lineage strains, promoting genetic diversity that facilitates survival under host oxidative stress and therapeutic pressure [20,22]. Investigating these variants can deepen our understanding of resistance evolution, identify predictive biomarkers for emerging MDR phenotypes, and reveal therapeutic targets within repair pathways to prevent mutational escape [21,23].
This study provides novel insight into the role of 3R genes in the emergence of drug resistance by analyzing SNP data from 175 Mtb isolates collected in Kazakhstan—a sentinel high-MDR/RR-TB region—focusing on the distribution and frequency of mutations across a predefined panel of 67 3R genes.

2. Results

2.1. Analysis of SNPs

Analysis of mutations in 3R genes among Mycobacterium tuberculosis strains resistant to various antimicrobial drugs revealed a pattern of non-synonymous variants potentially associated with resistance phenotypes (Table S1). Across the dataset, genes such as gyrA exhibited recurrent mutations linked to fluoroquinolone resistance, including Asp94Gly (observed in up to 92.3% of rifampicin-resistant strains and 87.5% of moxifloxacin-resistant strains at 0.25 mg/L) and Ala90Val (prevalent in 85.7% to 100% across multiple drug categories), consistent with established mechanisms of topoisomerase inhibition.
In broader DNA repair pathways, mutations such as Gly58Arg in mutT2 were ob-served at high frequencies across multiple resistance profiles. Similarly, the Ile245Thr mutation in recF, involved in homologous recombination and replication fork restart, was prevalent (up to 100% in certain subsets, including 83.0% in isoniazid-resistant isolates). Further patterns emerged in excision repair components, with uvrC displaying Val434Ala and Val289Ile mutations at high frequencies (e.g., 78.8% in streptomycin-resistant isolates). In our cohort of antibiotic-resistant Mycobacterium tuberculosis isolates, nearly all strains exhibited mutations in lig genes (with frequencies reaching 93.9% in pyrazinamide-resistant subsets). Additionally, the Phe358Leu mutation in Rv2090, was highly frequent (up to 100% in subsets like bedaquiline-resistant isolates and 83.0% in isoniazid-resistant strains).
Similarly, mutations in the dnaB gene exhibited high prevalence (ranging from 76.2% to 83.0%) among isolates resistant to core first-line drugs, including isoniazid, rifampicin, and ethambutol. Examination of replication-associated genes, including polA, revealed prevalent mutations such as Arg188Gly and Thr186Pro, occurring at rates of 70.1% to 83.0% in strains resistant to isoniazid, rifampicin, and ethambutol.
To provide a clear visualization of the distribution and frequency of single-nucleotide polymorphisms across the 67 targeted DNA replication, repair, and recombination (3R) genes in all 175 Mycobacterium tuberculosis isolates, we conducted a systematic analysis of mutation load per gene. This approach enabled the identification of highly variable loci as well as genes with rare but consistent mutations, potentially reflecting functional constraints or adaptive significance in the context of MDR phenotype emergence. The results of this analysis including the overall mutational profile, isolate-level distribution, and associations with clinical resistance patterns are presented (Figure 1, Figure 2, Figure 3 and Figure 4) (Tables S2 and S3).
The genes with the highest mutation counts are uvrB (9 mutations), gyrA (5 mutations), and polA (4 mutations). Although, dnaB, nucS, ligD, ligB, mutT2, nei, radA, recF, and Rv2090 each exhibit a single mutation in all isolates. Additionally, ligC and uvrC consistently show two mutations per isolate (Table S2).
The genes gyrA, polA, and uvrB (Figure 3 and Figure 4) appear to be under selective pressure and may play a significant role in the acquisition of antibiotic resistance, whereas nucS, ligD, and other DNA repair genes seem to be more conserved, suggesting they are less variable and less directly involved in resistance development. In addition to these novel DNA repair associations, our analysis identified known first- and second-line drug resistance determinants, validating the consistency of our findings with established resistance mechanisms.

2.2. Spectrum of Nucleotide Substitutions

To gain deeper insight into the molecular nature and potential drivers of the observed mutations, we systematically characterized the spectrum of nucleotide substitutions in two complementary contexts: first, within the 67 targeted DNA replication, repair, and recombination genes, and second, across the entire genome of the sequenced isolates for comparative reference. This parallel analysis was designed to reveal whether mutational signatures in DNA maintenance pathways exhibit distinct biases compared to genome-wide patterns, which could indicate pathway-specific selective pressures, heightened vulnerability to particular types of DNA damage or differential efficiency of repair mechanisms operating on these functionally critical loci (Figure 5a,b).
The analysis of base substitution patterns across all isolates showed that transitions involving guanine constituted the largest proportion of observed mutations. Together, G > C and G > A substitutions represented 41% of all recorded events in the dataset. Notably, transitions originating from thymine occurred less frequently, with T > C substitutions comprising 15.5% of the total. Within this group, G → C (20.4%) and G → A (20.7%) transitions were dominant, while G → T substitutions were rare (0.4%). Similarly, A → N transitions comprised 26% of all substitutions, primarily represented by A → C (15.4%) and A → G (10.7%), whereas A → T substitutions were nearly absent (0.1%). Mutations originating from cytosine and thymine were comparatively infrequent, including 16.7% C → T and 15.5% T → C transitions.
To address the relationship between lineage structure and mutation profiles, we constructed a phylogenetic tree representing five sublineages (L2.2.M4, L2.2.M4.5, L2.2.M4.9, L2.2.M4.9.1, and L2.2.M4.9.2) (Figure 6).
Analysis of the phylogenetic tree revealed distinct mutations across five genes among the isolates. Mutations in gyrA were detected in three isolates (CUS0000645 lib0, CUS0000687 lib0, CUS0000721 lib0), while uvrC mutations were also present in three isolates (CUS0000732 lib0, CUS0000686 lib0, CUS0000602 lib0). polA and ligC each harbored mutations in two isolates (polA: CUS0000655 lib0, CUS0000626 lib0; ligC: CUS0000630 lib0, CUS0000666 lib0), whereas uvrB exhibited a mutation in a single isolate (CUS0000586 lib0).

3. Discussion

The genomic analysis of 175 Mycobacterium tuberculosis isolates from Kazakhstan revealed a complex mutational landscape within genes responsible for DNA replication, repair, and recombination. These loci are essential for maintaining genomic integrity, yet they also serve as potential sources of variability that enable bacterial adaptation under antibiotic pressure [21,24,25]. The predominance of nonsynonymous substitutions in genes such as gyrA, uvrB, recF, and polA may suggest the influence of selective pressures potentially shaping the evolution of multidrug-resistant tuberculosis in high-burden settings (Table S4). The observation that gyrA exhibited recurrent mutations at codons 90 and 94, including Ala90Val and Asp94Gly, aligns with prior global reports linking these substitutions to fluoroquinolone resistance and impaired binding of DNA gyrase inhibitors [26,27,28]. These variants were more pronounced in strains resistant to moxifloxacin and levofloxacin, aligning with prior reports on gyrA alterations driving quinolone resistance in multidrug-resistant tuberculosis [29,30]. This consistency reinforces the idea that drug-driven selection continues to shape the M. tuberculosis genome across geographically diverse populations [1]. The accumulation of mutations within gyrA and other repair-related loci underscores the intimate interplay between mutagenesis and adaptation in M. tuberculosis. Collectively, these findings establish a critical link between compromised DNA repair fidelity and the evolution of multidrug-resistant and extensively drug-resistant tuberculosis, suggesting that early detection of variants in 3R genes could serve as valuable diagnostic markers to guide therapeutic decisions and mitigate the emergence of resistance [20,31]. Notably, one study [29] also mentioned a substitution at codon 95, although it was reported at a low frequency. In contrast, within our cohort, mutations at codon 95 were more frequently observed. Moreover, we additionally detected recurrent substitutions at codons 21 and 668 (Table S3). However, despite their repeated occurrence, we cannot confidently propose these positions as reliable resistance markers: in larger international datasets, their prevalence for several antibiotics does not exceed 95%, and in instances where these substitutions appear more common, the evidence is limited to only a few isolates, restricting interpretability.
While mutations were indeed detected in DNA repair genes such as mutT2, recF, and uvrC among the analyzed isolates, potentially indicating broader disruptions in repair fidelity that could indirectly support the emergence and persistence of antibiotic resistance, direct causal links remain unsubstantiated for the specific variants identified in this study. For instance, the Gly58Arg substitution in mutT2 is fixed in the Beijing sublineage of M. tuberculosis and serves solely as a phylogenetic marker, with no functional contribution to drug resistance. Although the Beijing genotype as a whole has been correlated with multidrug resistance in various global cohorts, this appears attributable to lineage-specific evolutionary pressures rather than the mutT2 Gly58Arg mutation itself [32,33]. Similarly, while mutations in recF have been implicated in altered DNA recombination and potential contributions to hypermutator states in M. tuberculosis, the Ile245Thr variant observed here lacks documented evidence of such effects or direct ties to antibiotic resistance, distinguishing it from other reported recF alterations associated with drug tolerance [20]. These findings underscore the need for functional validation to clarify whether these SNPs confer hypermutator phenotypes, as previously described in M. tuberculosis and other pathogens, or merely reflect neutral genetic drift. In this context, the consistent detection of substitutions in uvrC, a key component of the nucleotide excision repair pathway, is particularly noteworthy. Defective uvr function can impair the excision of oxidatively damaged nucleotides, leading to an accumulation of mutational load and potentially facilitating resistance evolution [34,35,36]. The enrichment of uvrC variants in streptomycin- and isoniazid-resistant isolates observed in this study supports the hypothesis that defective excision repair indirectly promotes antibiotic tolerance by increasing mutational diversity.
Genes involved in DNA ligation and non-homologous end-joining (NHEJ) showed particularly high mutation burdens. Variants in the lig family were detected in nearly all resistant strains, reaching 93.9% prevalence in pyrazinamide-resistant subsets. Disruption of these genes is expected to impair ligation efficiency during NHEJ and other repair pathways, thereby increasing genomic instability and mutational supply for adaptation under drug pressure [37]. Similarly, the Phe358Leu substitution in Rv2090 (a putative accessory factor in repair epistasis) achieved near-fixation in bedaquiline-resistant isolates (up to 100%) and 83.0% in isoniazid-resistant strains, where it has been implicated in novel epistatic interactions that enhance genomic plasticity and resistance evolution [38].
Replication fork progression and fidelity were also frequently compromised. The replicative helicase gene dnaB harbored mutations in 76.2–83.0% of isolates resistant to isoniazid, rifampicin, and ethambutol. In Escherichia coli, analogous dnaB defects dramatically elevate mutation rates and accelerate acquisition of rifampicin resistance [39]; however, no comparable evidence has yet been reported for Mycobacterium tuberculosis, and our findings therefore raise the possibility—still unconfirmed—of a similar mechanism operating in clinical strains. Likewise, polA (DNA polymerase I) exhibited recurrent nonsynonymous changes (e.g., Arg188Gly and Thr186Pro) at frequencies of 70.1–83.0% in the same resistance categories. Although these specific polA variants have not been functionally characterized in M. tuberculosis, engineered error-prone polA alleles in experimental systems have been shown to increase mutation rates in drug-target genes such as rpoB and atpE [40]. Further validation in M. tuberculosis would require targeted functional assays—such as assessing rifampicin mutation frequency in strains engineered to carry these polA substitutions—to determine whether they contribute to elevated mutational propensity in clinical isolates.
This distribution aligns with previous findings reporting a strong predominance of transitions, particularly G → A and C → T changes, in Mycobacterium tuberculosis. Such transitions are typically attributed to spontaneous deamination and oxidative DNA damage, both of which are recognized as major mutational forces in GC-rich bacterial genomes. The observed bias toward GC → AT conversions is consistent with the known mutational trend in M. tuberculosis, reflecting both intrinsic genome composition and repair dynamics.
Additionally, the high transition rate can be caused by oxidative stress. Antibiotic exposure has been shown to stimulate the production of reactive oxygen species (ROS), which preferentially target guanine—the most oxidation-prone base among the four nucleotides. This leads to the accumulation of G-related mutations, such as G → A or G → C substitutions, as observed in this study. The connection between ROS-mediated DNA damage and antibiotic resistance evolution has been established in various bacteria, including E. coli, where increased G:C → A:T transitions occur under antibiotic stress. Thus, the prevalence of guanine-based substitutions in our dataset supports the notion that oxidative damage contributes significantly to mutational dynamics and the adaptive evolution of resistance in M. tuberculosis [41]. Moreover, reactive oxygen species (ROS) generate 8-oxoG lesions, which are known to cause G → T mutations, as demonstrated in the mouse germ cell lineage. Consistent with this, regions with elevated recombination rates and single-nucleotide polymorphisms tend to coincide with areas enriched in 8-oxoG, suggesting that this oxidative lesion not only drives G → T substitutions but may also contribute to the increased frequency of recombination events in human genome [42,43].
The well-characterized 81 bp rifampicin resistance-determining region (RRDR) of the rpoB gene, mutations at codons 450 (S450L) and 445 (H445Y) are most commonly associated with RIF resistance. Although some reports noted C → T, A → G, and C → A mutations in strains with defective DNA repair systems (e.g., mutY variants), the dominant role of oxidative stress and spontaneous base modification appears to be a more universal mechanism influencing the mutation spectrum in both clinical and laboratory strains [20,44].
Overall, the most prevalent nucleotide change in M. tuberculosis is the G/C > A/T transition, likely resulting from oxidative damage that the bacterium experiences inside host macrophages. This pattern, first identified in nonhuman primate studies, represents a major mutation type that spreads under relaxed selection in various bacterial species, including M. tuberculosis. The genome’s exceptionally high GC content (around 65%) and its abundance of GC-rich homopolymeric regions are thought to further shape and reinforce this mutational bias [45,46].
A notable feature of the mutational spectrum was the strong predominance of G/C. A/T transitions, accounting for nearly half of all observed substitutions. This bias is consistent with previous findings indicating that oxidative stress within host macrophages acts as a dominant mutagenic force in M. tuberculosis, preferentially targeting guanine residues [47]. Notably, this bias is stronger in multidrug-resistant isolates compared to drug-susceptible ones, as evidenced by higher overall mutation rates in MDR-associated lineages like Beijing and an enriched spectrum of oxidative transitions during both latent and active phases [48,49]. Mutation bias modeling further shows that such shifts proportionally shape adaptive evolution in MDR strains under antibiotic pressure, amplifying resistance trajectories [50]. Reactive oxygen species (ROS) produced during immune responses can oxidize guanine to 8-oxoguanine, which mispairs with adenine during replication, resulting in characteristic G → T or G → A transitions [51]. The observed pattern of guanine-centered mutations in the current dataset thus reflects an adaptive balance between oxidative DNA damage and the limited capacity of the mycobacterial repair machinery to correct such lesions. Given the exceptionally high GC content of the M. tuberculosis genome (approximately 65%), the oxidative environment within macrophages likely intensifies this mutational bias, further influencing the trajectory of resistance evolution.
Interestingly, the conservation of nucS, a noncanonical mismatch repair factor, is consistent with its recently described role in limiting transition mutations and maintaining genomic fidelity [52]. Experimental inactivation of the noncanonical mismatch repair gene nucS in Mycobacterium abscessus has been demonstrated to induce a hypermutator phenotype, characterized by a predominance of transition mutations—patterns that closely mirror those observed in our dataset [53]. However, nucS itself did not show any functionally significant mutations in the 175 isolates analyzed in this study. This complete absence of non-synonymous changes indicates that nucS is under strong purifying selection and experiences tight functional constraint across the studied population. The few nucleotide substitutions identified were silent and present only in a subset of isolates. Although the S144R substitution is observed relative to the H37Rv reference genome, arginine at this position represents the consensus state among Mycobacterium species, indicating that this variant is unlikely to impair NucS function. Therefore, the accumulation of transition mutations in other 3R genes is more likely attributable to disruptions in alternative DNA repair pathways, including downstream effectors or stress-responsive modulators that indirectly compromise mismatch repair efficiency. This interpretation highlights the intricate balance between genomic stability and adaptive mutational plasticity in mycobacteria, enabling enhanced evolvability under antibiotic selective pressures without direct alterations to core mismatch repair components.
Altogether, the findings presented in this study illustrate how the interplay between oxidative stress, impaired repair systems, and selective drug pressure shapes the mutational dynamics of M. tuberculosis. The convergence of these processes fosters both short-term adaptation through direct resistance mutations and long-term genomic plasticity, enhancing the bacterium’s ability to survive under therapeutic and immune stress. Given Kazakhstan’s high MDR-TB burden, the identification of such mutational signatures in local isolates emphasizes the urgent need to integrate genomic surveillance into routine diagnostic and public health frameworks. Moreover, early detection of SNPs in 3R genes could serve as predictive markers of hypermutability, offering a new avenue for stratifying patients at risk of resistance amplification during treatment. Future studies combining functional assays with comparative genomics will be crucial to elucidate the mechanistic consequences of these variants and to determine whether targeting DNA repair pathways could represent a viable adjunct strategy for combating drug-resistant tuberculosis.

4. Materials and Methods

4.1. Data Source

Genomic sequences of Mycobacterium tuberculosis were obtained from the Laboratory of Proteomics and Mass Spectrometry at the National Center for Biotechnology of the Republic of Kazakhstan. All sequences were provided in FASTA format and used as the primary data source for downstream bioinformatic analysis.

4.2. Genomic Data Processing

Filtering and Preprocessing Raw genomic data were processed using custom Python scripts developed in Python v3.13. The workflow was implemented in Visual Studio Code v1.106.2 and included an initial filtering step to identify sequences containing single-nucleotide polymorphisms (SNPs). Only high-confidence SNPs with sufficient sequence coverage and quality scores were retained for further analysis.

4.3. Local Gene Database Construction

A local gene database was constructed to include genes potentially associated with the development of antibiotic resistance in Mycobacterium tuberculosis. This database served as a reference for subsequent comparisons and filtering. Genes were selected based on the prior literature, known resistance-associated loci, and recurrent mutation patterns identified in the current dataset.

4.4. Bioinformatic Analysis

Filtered sequences were aligned against the local gene database to detect matches indicative of potential antibiotic resistance-related mutations. The resulting dataset was used to quantify the total number of SNPs, transversions, and transitions. Mutation frequencies and types were summarized using Python-based statistical libraries (e.g., pandas, numpy, matplotlib).

4.5. Visualization and Statistical Interpretation

To visualize the overall mutation landscape, pie charts were generated to show the proportion of transition and transversion events. The total and unique mutation counts were calculated for each isolate.
A heatmap was then created to display the distribution of mutations across all analyzed M. tuberculosis genomes, highlighting patterns of variation among isolates. A three-dimensional (3D) representation of mutation frequency was produced, applying a threshold filter to visualize genes exceeding a defined mutation count.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics15010026/s1, Supplementary Tables S1–S4.

Author Contributions

Conceptualization, S.A. and A.S.; methodology, S.T.; software, S.T.; validation, S.A., A.T. and A.S.; formal analysis, S.T. and U.Z.; investigation, S.A.; resources, P.T. and D.A.; writing—original draft preparation, A.S. and B.Y.; writing—review and editing, S.A.; visualization, S.T.; supervision, S.A.; project administration, S.A. and A.S.; funding acquisition, S.A. and A.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan Grant Nos. AP19680500 and AP23488467.

Institutional Review Board Statement

The study was approved by the National Center for Biotechnology Institutional Review Ethics Committee (NCB-IREC 04-03/07082020; approved 7 August 2020). All principles of the Declaration of Helsinki for Biomedical Research Involving Human Participants were adhered to during the sample collection, based on good medical and laboratory practices.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. World Health Organization. Global Tuberculosis Report 2025; World Health Organization: Geneva, Switzerland, 2025. [Google Scholar]
  2. Bagcchi, S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe 2023, 4, e20. [Google Scholar] [CrossRef]
  3. Dean, A.S.; Tosas Auguet, O.; Glaziou, P.; Zignol, M.; Ismail, N.; Kasaeva, T.; Floyd, K. 25 years of surveillance of drug-resistant tuberculosis: Achievements, challenges, and way forward. Lancet Infect. Dis. 2022, 22, e191–e196. [Google Scholar] [CrossRef] [PubMed]
  4. Akhmetova, A.; Bismilda, V.; Chingissova, L.; Filipenko, M.; Akilzhanova, A.; Kozhamkulov, U. Prevalence of Beijing Central Asian/Russian Cluster 94–32 among Multidrug-Resistant M. tuberculosis in Kazakhstan. Antibiotics 2023, 13, 9. [Google Scholar] [CrossRef]
  5. World Health Organization. WHO Global Lists of High Burden Countries for TB, Multidrug/Rifampicin-Resistant TB (MDR/RR-TB) and TB/HIV, 2021–2025; World Health Organization: Geneva, Switzerland, 2021. [Google Scholar]
  6. Auganova, D.; Atavliyeva, S.; Gharbi, N.; Zholdybayeva, E.; Skiba, Y.; Akisheva, A.; Tsepke, A.; Alenova, A.; Guyeux, C.; Wirth, T.; et al. Genomic characterization and epidemiology of Mycobacterium tuberculosis lineage 2 isolates from Kazakhstan. Sci. Rep. 2025, 15, 37715. [Google Scholar] [CrossRef]
  7. Atavliyeva, S.; Auganova, D.; Tarlykov, P. Genetic diversity, evolution and drug resistance of Mycobacterium tuberculosis lineage 2. Front. Microbiol. 2024, 15, 1384791. [Google Scholar] [CrossRef]
  8. van den Hof, S.; Collins, D.; Hafidz, F.; Beyene, D.; Tursynbayeva, A.; Tiemersma, E. The socioeconomic impact of multidrug resistant tuberculosis on patients: Results from Ethiopia, Indonesia and Kazakhstan. BMC Infect. Dis. 2016, 16, 470. [Google Scholar] [CrossRef]
  9. Kozhamkulov, U.; Iglikova, S.; Rakisheva, A.; Almazan, J. Multidrug-Resistant Tuberculosis in Central Asia and Predominant Beijing Lineage, Challenges in Diagnosis, Treatment Barriers, and Infection Control Strategies: An Integrative Review. Antibiotics 2025, 14, 673. [Google Scholar] [CrossRef] [PubMed]
  10. Ford, C.B.; Shah, R.R.; Maeda, M.K.; Gagneux, S.; Murray, M.B.; Cohen, T.; Johnston, J.C.; Gardy, J.; Lipsitch, M.; Fortune, S.M. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat. Genet. 2013, 45, 784–790. [Google Scholar] [CrossRef] [PubMed]
  11. Cohen, K.A.; Manson, A.L.; Desjardins, C.A.; Abeel, T.; Earl, A.M. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: Progress, promise, and challenges. Genome Med. 2019, 11, 45. [Google Scholar] [CrossRef]
  12. McGrath, M.; Gey van Pittius, N.C.; van Helden, P.D.; Warren, R.M.; Warner, D.F. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 2014, 69, 292–302. [Google Scholar] [CrossRef]
  13. Hawkey, J.; Wyres, K.L.; Judd, L.M.; Harshegyi, T.; Blakeway, L.; Wick, R.R.; Jenney, A.W.J.; Holt, K.E. ESBL plasmids in Klebsiella pneumoniae: Diversity, transmission and contribution to infection burden in the hospital setting. Genome Med. 2022, 14, 97. [Google Scholar] [CrossRef]
  14. Gagneux, S. Ecology and evolution of Mycobacterium tuberculosis. Nat. Rev. Microbiol. 2018, 16, 202–213. [Google Scholar] [CrossRef]
  15. Cohen, K.A.; Abeel, T.; Manson McGuire, A.; Desjardins, C.A.; Munsamy, V.; Shea, T.P.; Walker, B.J.; Bantubani, N.; Almeida, D.V.; Alvarado, L.; et al. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. PLoS Med. 2015, 12, e1001880. [Google Scholar] [CrossRef] [PubMed]
  16. Belay, W.Y.; Getachew, M.; Tegegne, B.A.; Teffera, Z.H.; Dagne, A.; Zeleke, T.K.; Abebe, R.B.; Gedif, A.A.; Fenta, A.; Yirdaw, G.; et al. Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: A review. Front. Pharmacol. 2024, 15, 1444781. [Google Scholar] [CrossRef]
  17. Manson, A.L.; Cohen, K.A.; Abeel, T.; Desjardins, C.A.; Armstrong, D.T.; Barry, C.E., 3rd; Brand, J.; Chapman, S.B.; Cho, S.N.; Gabrielian, A.; et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat. Genet. 2017, 49, 395–402. [Google Scholar] [CrossRef]
  18. Walker, T.M.; Kohl, T.A.; Omar, S.V.; Hedge, J.; Del Ojo Elias, C.; Bradley, P.; Iqbal, Z.; Feuerriegel, S.; Niehaus, K.E.; Wilson, D.J.; et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: A retrospective cohort study. Lancet Infect. Dis. 2015, 15, 1193–1202. [Google Scholar] [CrossRef]
  19. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biol. 2022, 20, e3001721. [CrossRef]
  20. Naz, S.; Paritosh, K.; Sanyal, P.; Khan, S.; Singh, Y.; Varshney, U.; Nandicoori, V.K. GWAS and functional studies suggest a role for altered DNA repair in the evolution of drug resistance in Mycobacterium tuberculosis. eLife 2023, 12, e75860. [Google Scholar] [CrossRef]
  21. Zein-Eddine, R.; Le Meur, A.; Skouloubris, S.; Jelsbak, L.; Refrégier, G.; Myllykallio, H. Genome wide analyses reveal the role of mutator phenotypes in Mycobacterium tuberculosis drug resistance emergence. npj Antimicrob. Resist. 2025, 3, 35. [Google Scholar] [CrossRef]
  22. Furió, V.; Moreno-Molina, M.; Chiner-Oms, Á.; Villamayor, L.M.; Torres-Puente, M.; Comas, I. An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis. Commun. Biol. 2021, 4, 1322. [Google Scholar] [CrossRef]
  23. Reiche, M.A.; Warner, D.F.; Mizrahi, V. Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis. Front. Mol. Biosci. 2017, 4, 75. [Google Scholar] [CrossRef]
  24. Jones, R.M.; Adams, K.N.; Eldesouky, H.E.; Sherman, D.R. The evolving biology of Mycobacterium tuberculosis drug resistance. Front. Cell. Infect. Microbiol. 2022, 12, 1027394. [Google Scholar] [CrossRef] [PubMed]
  25. Payne, J.L.; Menardo, F.; Trauner, A.; Borrell, S.; Gygli, S.M.; Loiseau, C.; Gagneux, S.; Hall, A.R. Transition bias influences the evolution of antibiotic resistance in Mycobacterium tuberculosis. PLoS Biol. 2019, 17, e3000265. [Google Scholar] [CrossRef]
  26. Maruri, F.; Sterling, T.R.; Kaiga, A.W.; Blackman, A.; van der Heijden, Y.F.; Mayer, C.; Cambau, E.; Aubry, A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 2012, 67, 819–831. [Google Scholar] [CrossRef]
  27. Chen, J.; Chen, Z.; Li, Y.; Xia, W.; Chen, X.; Chen, T.; Zhou, L.; Xu, B.; Xu, S. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz. J. Infect. Dis. Off. Publ. Braz. Soc. Infect. Dis. 2012, 16, 136–141. [Google Scholar] [CrossRef]
  28. Kabir, S.; Tahir, Z.; Mukhtar, N.; Sohail, M.; Saqalein, M.; Rehman, A. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. BMC Pulm. Med. 2020, 20, 138. [Google Scholar] [CrossRef] [PubMed]
  29. Willby, M.; Chopra, P.; Lemmer, D.; Klein, K.; Dalton, T.L.; Engelthaler, D.M.; Cegielski, J.P.; Posey, J.E. Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis. Antimicrob. Agents Chemother. 2020, 65, e01663-20. [Google Scholar] [CrossRef]
  30. Willby, M.; Sikes, R.D.; Malik, S.; Metchock, B.; Posey, J.E. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2015, 59, 5427–5434. [Google Scholar] [CrossRef]
  31. Shenagari, M.; Bakhtiari, M.; Mojtahedi, A.; Atrkar Roushan, Z. High frequency of mutations in gyrA gene associated with quinolones resistance in uropathogenic Escherichia coli isolates from the north of Iran. Iran. J. Basic Med. Sci. 2018, 21, 1226–1231. [Google Scholar] [CrossRef]
  32. Moreland, N.J.; Charlier, C.; Dingley, A.J.; Baker, E.N.; Lott, J.S. Making sense of a missense mutation: Characterization of MutT2, a Nudix hydrolase from Mycobacterium tuberculosis, and the G58R mutant encoded in W-Beijing strains of M. tuberculosis. Biochemistry 2009, 48, 699–708. [Google Scholar] [CrossRef] [PubMed]
  33. Morey-León, G.; Andrade-Molina, D.; Fernández-Cadena, J.C.; Berná, L. Comparative genomics of drug-resistant strains of Mycobacterium tuberculosis in Ecuador. BMC Genom. 2022, 23, 844. [Google Scholar] [CrossRef]
  34. Thakur, M.; Agarwal, A.; Muniyappa, K. The intrinsic ATPase activity of Mycobacterium tuberculosis UvrC is crucial for its damage-specific DNA incision function. FEBS J. 2021, 288, 1179–1200. [Google Scholar] [CrossRef]
  35. Thakur, M.; Parulekar, R.S.; Barale, S.S.; Sonawane, K.D.; Muniyappa, K. Interrogating the substrate specificity landscape of UvrC reveals novel insights into its non-canonical function. Biophys. J. 2022, 121, 3103–3125. [Google Scholar] [CrossRef]
  36. Naz, S.; Datta, D.; Khan, S.; Singh, Y.; Nandicoori, V.K.; Kumar, D. A clinical mutation in uvrA, A DNA repair gene, confers survival advantage to Mycobacterium tuberculosisin the host. Biorxiv Prepr. Serv. Biol. 2024. [Google Scholar] [CrossRef]
  37. Gong, C.; Martins, A.; Bongiorno, P.; Glickman, M.; Shuman, S. Biochemical and genetic analysis of the four DNA ligases of mycobacteria. J. Biol. Chem. 2004, 279, 20594–20606. [Google Scholar] [CrossRef]
  38. Kavvas, E.S.; Catoiu, E.; Mih, N.; Yurkovich, J.T.; Seif, Y.; Dillon, N.; Heckmann, D.; Anand, A.; Yang, L.; Nizet, V.; et al. Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance. Nat. Commun. 2018, 9, 4306. [Google Scholar] [CrossRef]
  39. Behrmann, M.S.; Perera, H.M.; Hoang, J.M.; Venkat, T.A.; Visser, B.J.; Bates, D.; Trakselis, M.A. Targeted chromosomal Escherichia coli:dnaB exterior surface residues regulate DNA helicase behavior to maintain genomic stability and organismal fitness. PLoS Genet. 2021, 17, e1009886. [Google Scholar] [CrossRef]
  40. Feng, S.; Liang, L.; Shen, C.; Lin, D.; Li, J.; Lyu, L.; Liang, W.; Zhong, L.L.; Cook, G.M.; Doi, Y.; et al. A CRISPR-guided mutagenic DNA polymerase strategy for the detection of antibiotic-resistant mutations in M. tuberculosis. Mol. Ther. Nucleic Acids 2022, 29, 354–367. [Google Scholar] [CrossRef]
  41. Wang, Z.Y.; Xiong, M.; Fu, L.Y.; Zhang, H.Y. Oxidative DNA damage is important to the evolution of antibiotic resistance: Evidence of mutation bias and its medicinal implications. J. Biomol. Struct. Dyn. 2013, 31, 729–733. [Google Scholar] [CrossRef]
  42. Ohno, M.; Sakumi, K.; Fukumura, R.; Furuichi, M.; Iwasaki, Y.; Hokama, M.; Ikemura, T.; Tsuzuki, T.; Gondo, Y.; Nakabeppu, Y. 8-oxoguanine causes spontaneous de novo germline mutations in mice. Sci. Rep. 2014, 4, 4689. [Google Scholar] [CrossRef]
  43. Ohno, M.; Miura, T.; Furuichi, M.; Tominaga, Y.; Tsuchimoto, D.; Sakumi, K.; Nakabeppu, Y. A genome-wide distribution of 8-oxoguanine correlates with the preferred regions for recombination and single nucleotide polymorphism in the human genome. Genome Res. 2006, 16, 567–575. [Google Scholar] [CrossRef]
  44. Kumar, S.; Jena, L. Understanding Rifampicin Resistance in Tuberculosis through a Computational Approach. Genom. Inform. 2014, 12, 276–282. [Google Scholar] [CrossRef]
  45. Yar, A.M.; Zaman, G.; Hussain, A.; Changhui, Y.; Rasul, A.; Hussain, A.; Bo, Z.; Bokhari, H.; Ibrahim, M. Comparative Genome Analysis of 2 Mycobacterium Tuberculosis Strains from Pakistan: Insights Globally Into Drug Resistance, Virulence, and Niche Adaptation. Evol. Bioinform. 2018, 14, 1176934318790252. [Google Scholar] [CrossRef] [PubMed]
  46. Koleske, B.N.; Jacobs, W.R., Jr.; Bishai, W.R. The Mycobacterium tuberculosis genome at 25 years: Lessons and lingering questions. J. Clin. Investig. 2023, 133, e173156. [Google Scholar] [CrossRef] [PubMed]
  47. Lyu, L.D.; Tang, B.K.; Fan, X.Y.; Ma, H.; Zhao, G.P. Mycobacterial MazG safeguards genetic stability via housecleaning of 5-OH-dCTP. PLoS Pathog. 2013, 9, e1003814. [Google Scholar] [CrossRef]
  48. Hakamata, M.; Takihara, H.; Iwamoto, T.; Tamaru, A.; Hashimoto, A.; Tanaka, T.; Kaboso, S.A.; Gebretsadik, G.; Ilinov, A.; Yokoyama, A.; et al. Higher genome mutation rates of Beijing lineage of Mycobacterium tuberculosis during human infection. Sci. Rep. 2020, 10, 17997. [Google Scholar] [CrossRef]
  49. Ford, C.B.; Lin, P.L.; Chase, M.R.; Shah, R.R.; Iartchouk, O.; Galagan, J.; Mohaideen, N.; Ioerger, T.R.; Sacchettini, J.C.; Lipsitch, M.; et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 2011, 43, 482–486. [Google Scholar] [CrossRef]
  50. Cano, A.V.; Rozhoňová, H.; Stoltzfus, A.; McCandlish, D.M.; Payne, J.L. Mutation bias shapes the spectrum of adaptive substitutions. Proc. Natl. Acad. Sci. USA 2022, 119, e2119720119. [Google Scholar] [CrossRef]
  51. Neeley, W.L.; Essigmann, J.M. Mechanisms of formation, genotoxicity, and mutation of guanine oxidation products. Chem. Res. Toxicol. 2006, 19, 491–505. [Google Scholar] [CrossRef] [PubMed]
  52. Cebrián-Sastre, E.; Martín-Blecua, I.; Gullón, S.; Blázquez, J.; Castañeda-García, A. Control of Genome Stability by EndoMS/NucS-Mediated Non-Canonical Mismatch Repair. Cells 2021, 10, 1314. [Google Scholar] [CrossRef]
  53. Fressatti Cardoso, R.; Martín-Blecua, I.; Pietrowski Baldin, V.; Meneguello, J.E.; Valverde, J.R.; Blázquez, J.; Castañeda-García, A. Noncanonical Mismatch Repair Protein NucS Modulates the Emergence of Antibiotic Resistance in Mycobacterium abscessus. Microbiol. Spectr. 2022, 10, e0222822. [Google Scholar] [CrossRef] [PubMed]
Figure 1. The distribution of mutations across the examined genes in 175 isolates. The extremes of the mutation count appear as peaks on the graph.
Figure 1. The distribution of mutations across the examined genes in 175 isolates. The extremes of the mutation count appear as peaks on the graph.
Antibiotics 15 00026 g001
Figure 2. The distribution of mutations among recombination-associated genes.
Figure 2. The distribution of mutations among recombination-associated genes.
Antibiotics 15 00026 g002
Figure 3. The distribution of mutations among replication-associated genes.
Figure 3. The distribution of mutations among replication-associated genes.
Antibiotics 15 00026 g003
Figure 4. The distribution of mutations among repair-associated genes.
Figure 4. The distribution of mutations among repair-associated genes.
Antibiotics 15 00026 g004
Figure 5. (a) Description of nucleotide substitutions among 3R genes; (b) nucleotide substitutions among whole genome.
Figure 5. (a) Description of nucleotide substitutions among 3R genes; (b) nucleotide substitutions among whole genome.
Antibiotics 15 00026 g005
Figure 6. The phylogenetic reconstruction encompassing five sublineages—L2.2.M4, L2.2.M4.5, L2.2.M4.9, L2.2.M4.9.1, and L2.2.M4.9.2—reveals a set of sublineage-specific mutations distributed across several genes, including polA, gyrA, uvrC, uvrB, and ligC.
Figure 6. The phylogenetic reconstruction encompassing five sublineages—L2.2.M4, L2.2.M4.5, L2.2.M4.9, L2.2.M4.9.1, and L2.2.M4.9.2—reveals a set of sublineage-specific mutations distributed across several genes, including polA, gyrA, uvrC, uvrB, and ligC.
Antibiotics 15 00026 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Timochshuk, S.; Shamukhan, A.; Yakupov, B.; Auganova, D.; Zein, U.; Turgimbayeva, A.; Tarlykov, P.; Abeldenov, S. Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance in Mycobacterium tuberculosis Isolates from Kazakhstan. Antibiotics 2026, 15, 26. https://doi.org/10.3390/antibiotics15010026

AMA Style

Timochshuk S, Shamukhan A, Yakupov B, Auganova D, Zein U, Turgimbayeva A, Tarlykov P, Abeldenov S. Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance in Mycobacterium tuberculosis Isolates from Kazakhstan. Antibiotics. 2026; 15(1):26. https://doi.org/10.3390/antibiotics15010026

Chicago/Turabian Style

Timochshuk, Savva, Aldan Shamukhan, Bakhtiyar Yakupov, Dana Auganova, Ulan Zein, Aigerim Turgimbayeva, Pavel Tarlykov, and Sailau Abeldenov. 2026. "Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance in Mycobacterium tuberculosis Isolates from Kazakhstan" Antibiotics 15, no. 1: 26. https://doi.org/10.3390/antibiotics15010026

APA Style

Timochshuk, S., Shamukhan, A., Yakupov, B., Auganova, D., Zein, U., Turgimbayeva, A., Tarlykov, P., & Abeldenov, S. (2026). Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance in Mycobacterium tuberculosis Isolates from Kazakhstan. Antibiotics, 15(1), 26. https://doi.org/10.3390/antibiotics15010026

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop